Diminished adherence of sickle erythrocytes to cultured vascular endothelium by piracetam

Nalbandian, Robert M.; Henry, Raymond L.; Burek, C. Lynne; Diglio, Clement A.; Goldman, Arnold I.; Taylor, Gregory; Hoffman, William H.

doi:10.1002/ajh.2830150206

Cited by 23 publications

(15 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Reduced erythrocyte adhesion to the endothelial wall following piracetam administration was reported by Nalbandian and colleagues (57). Blood taken from healthy individuals and from those with sickle cell anemia was incubated with saline or 1.5 mmol/L of piracetam for at least 30 min prior to additional incubation with endothelial cell culture (57).…”

Section: Effects On Erythrocytesmentioning

confidence: 87%

“…Studies suggest that piracetam exerts a number of effects on erythrocytes, such as decreased adhesion to endothelium (57). These effects are likely to facilitate movement of erythrocytes through the circulation.…”

Section: Effects On Erythrocytesmentioning

confidence: 99%

“…Blood taken from healthy individuals and from those with sickle cell anemia was incubated with saline or 1.5 mmol/L of piracetam for at least 30 min prior to additional incubation with endothelial cell culture (57). Piracetam significantly reduced adhesion to endothelial cells in both normal (normalized adherence = 1.0 and 0.88 for saline and piracetam, respectively, p < 0.02), and sickle cell preparations (normalized adherence = 1.15 and 0.84 for saline and piracetam, respectively, p < 0.02).…”

Section: Effects On Erythrocytesmentioning

confidence: 99%

See 2 more Smart Citations

Piracetam: A Review of Pharmacological Properties and Clinical Uses

2005

View full text Add to dashboard Cite

Piracetam, a derivative of the neurotransmitter ã-aminobutyric acid (GABA), has a variety of physiological effects that may result, at least in part, from the restoration of cell membrane fluidity. At a neuronal level, piracetam modulates neurotransmission in a range of transmitter systems (including cholinergic and glutamatergic), has neuroprotective and anticonvulsant properties, and improves neuroplasticity. At a vascular level, it appears to reduce erythrocyte adhesion to vascular endothelium, hinder vasospasm, and facilitate microcirculation. This diverse range of physiological effects is consistent with its use in a range of clinical indications. Its efficacy is documented in cognitive disorders and dementia, vertigo, cortical myoclonus, dyslexia, and sickle cell anemia. While high doses are sometimes necessary, piracetam is well tolerated.

show abstract

Section: Effects On Erythrocytesmentioning

confidence: 87%

Section: Effects On Erythrocytesmentioning

confidence: 99%

Section: Effects On Erythrocytesmentioning

confidence: 99%

See 1 more Smart Citation

Piracetam: A Review of Pharmacological Properties and Clinical Uses

2005

View full text Add to dashboard Cite

show abstract

“…6. Влияние на сосудистые механизмы ■ Уменьшение адгезии эритроцитов к эндотелию стен-ки сосудов [21]. ■ Влияние на сосудистую стенку.…”

Section: влияние на энергетический обмен в клеткеunclassified

Possibilities to Use a Fixed Combination of Piracetam and Cinnarizine in Neurological Practice

Titova¹

2017

Med. sov.

View full text Add to dashboard Cite

ПРАКТИКА ВВЕДЕНИЕВ последние годы в неврологии, как и во многих других областях медицины, все бо льшую популярность завоевы-вают комбинированные препараты, содержащие два активных компонента. В первую очередь это связано с открытием новых механизмов, лежащих в основе невро-логических расстройств. Вовлечение нескольких звеньев в патогенез большинства заболеваний нервной системы на практике выражается в необходимости использования препаратов с разными точками приложения, с разными механизмами действия. Как следствие одновременного назначения нескольких препаратов, невролог нередко сталкивается с проблемой низкой приверженности к лечению. Достижением современной фармакотерапии является разработка и внедрение в клиническую практи-ку препаратов с комбинированным составом, т. е. оптими-зация лечебного процесса. Такие лекарственные формы включают в себя активные компоненты со сбалансиро-ванным разносторонним влиянием на патологические процессы заболевания, с одной стороны, и в адекватных дозах, не приводящих к усилению побочных эффектов или развитию непредсказуемых фармакологических вза-имодействий, с другой стороны. Примером такого сочета-

show abstract

“…Similarities between the vaso-occlusive crisis and senile vasculopathy, and between piracetam, a cyclic derivative of γ-aminobutyric acid, and urea led to studies on piracetam in sickle cell disease. Most of the in vitrostudies with piracetam, performed mainly during the period of 1974–1992, have shown a reversal of sickling, a reduction in blood viscosity, an increase in erythrocyte elasticity, a reduction in adherence to the vascular endothelium, inhibition of platelet aggregation, water reduction and cell potassium loss [14,15,16,17,18,19]. An in vitro study performed in 1979 showed the drug to be ineffective [20].…”

Section: Introductionmentioning

confidence: 99%

Inefficacy of Piracetam in the Prevention of Painful Crises in Children and Adolescents with Sickle Cell Disease

Alvim

Viana²,

Pires³

et al. 2005

Acta Haematol

View full text Add to dashboard Cite

Analgesia and hydration remain the only safe treatment for painful crises of sickle cell disease; hydroxyurea is effective, but the toxicity is still a problem. Piracetam is a nootropic drug that has reportedly been effective and non-toxic in sickle cell patients, but most studies were not placebo-controlled and included a small number of patients. The present study evaluated the drug in a double-blind crossed placebo-controlled clinical trial in 73 children and adolescents suffering from moderate to severe painful crises for 13 months. Information regarding frequency and severity of pain was acquired through monthly clinical evaluation, visits and house calls, and 4,300 weekly questionnaires filled out by the patients in their domiciles. A monthly pain score was calculated for each patient. Pain was the most frequent adverse manifestation of the disease stressing its significant bio-psycho-social impact. Although nearly all patients and relatives reported a better clinical course throughout the whole study, the drug was ineffective in the prevention of painful crises. This placebo effect may be ascribed to an unplanned and unsystematic ‘cognitive-behavioural’ management of the children. The pain score in the second semester of the study – both in the experimental and in the control groups – was significantly smaller than that in the first semester. In conclusion, piracetam was found to be ineffective in the prevention of painful crises; a powerful placebo effect due to adequate patient care was demonstrated.

show abstract

Diminished adherence of sickle erythrocytes to cultured vascular endothelium by piracetam

Cited by 23 publications

References 12 publications

Piracetam: A Review of Pharmacological Properties and Clinical Uses

Piracetam: A Review of Pharmacological Properties and Clinical Uses

Possibilities to Use a Fixed Combination of Piracetam and Cinnarizine in Neurological Practice

Inefficacy of Piracetam in the Prevention of Painful Crises in Children and Adolescents with Sickle Cell Disease

Contact Info

Product

Resources

About